ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank57
3Y CAGR+47.8%
5Y CAGR+13.6%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+47.8%/yr
vs -30.7%/yr prior
5Y CAGR
+13.6%/yr
Recent acceleration
Acceleration
+78.5pp
Accelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM25.55%+148.7%
202410.27%-53.1%
202321.90%+176.7%
20227.91%+449.0%
20211.44%-89.3%
202013.49%-54.1%
201929.40%-14.2%
201834.28%+6.1%
201732.32%-26.2%
201643.78%-